Clinical remission among severe asthmatics on monoclonal antibody therapy: real-world outcomes at 2 years.

Fred Fyles; Rachel Burton; Amy Nuttall; Hannah Joplin; Laura Watkins; Hassan Burhan

doi:10.1183/23120541.00261-2024

Clinical remission among severe asthmatics on monoclonal antibody therapy: real-world outcomes at 2 years.

Fred Fyles
, Rachel Burton
, Amy Nuttall
, Hannah Joplin
, Laura Watkins
, Hassan Burhan

Clinical Sciences

Liverpool School of Tropical Medicine

Research output: Contribution to journal › Letter › peer-review

3 Citations (Scopus)

Abstract

Real-world data suggest clinical remission is a feasible treatment goal of monoclonal antibody therapy. Evidence of ongoing response post-12 months may be used to inform treatment decisions. Further work is needed to standardise criteria for remission. https://bit.ly/4cA6TkG.

Original language	English
Article number	00261-2024
Pages (from-to)	e00261-2024
Journal	ERJ Open Research
Volume	10
Issue number	6
DOIs	https://doi.org/10.1183/23120541.00261-2024
Publication status	Published - 1 Nov 2024

Access to Document

10.1183/23120541.00261-2024Licence: CC BY

PMC11647906Final published version, 270 KBLicence: CC BY

Cite this

@article{5851c111751f4a528b4172cc4ca8135c,

title = "Clinical remission among severe asthmatics on monoclonal antibody therapy: real-world outcomes at 2 years.",

abstract = "Real-world data suggest clinical remission is a feasible treatment goal of monoclonal antibody therapy. Evidence of ongoing response post-12 months may be used to inform treatment decisions. Further work is needed to standardise criteria for remission. https://bit.ly/4cA6TkG.",

author = "Fred Fyles and Rachel Burton and Amy Nuttall and Hannah Joplin and Laura Watkins and Hassan Burhan",

year = "2024",

month = nov,

day = "1",

doi = "10.1183/23120541.00261-2024",

language = "English",

volume = "10",

pages = "e00261--2024",

journal = "ERJ Open Research",

issn = "2312-0541",

publisher = "European Respiratory Society",

number = "6",

}

TY - JOUR

T1 - Clinical remission among severe asthmatics on monoclonal antibody therapy: real-world outcomes at 2 years.

AU - Fyles, Fred

AU - Burton, Rachel

AU - Nuttall, Amy

AU - Joplin, Hannah

AU - Watkins, Laura

AU - Burhan, Hassan

PY - 2024/11/1

Y1 - 2024/11/1

N2 - Real-world data suggest clinical remission is a feasible treatment goal of monoclonal antibody therapy. Evidence of ongoing response post-12 months may be used to inform treatment decisions. Further work is needed to standardise criteria for remission. https://bit.ly/4cA6TkG.

AB - Real-world data suggest clinical remission is a feasible treatment goal of monoclonal antibody therapy. Evidence of ongoing response post-12 months may be used to inform treatment decisions. Further work is needed to standardise criteria for remission. https://bit.ly/4cA6TkG.

U2 - 10.1183/23120541.00261-2024

DO - 10.1183/23120541.00261-2024

M3 - Letter

SN - 2312-0541

VL - 10

SP - e00261-2024

JO - ERJ Open Research

JF - ERJ Open Research

IS - 6

M1 - 00261-2024

ER -

Clinical remission among severe asthmatics on monoclonal antibody therapy: real-world outcomes at 2 years.

Abstract

Access to Document

Fingerprint

Cite this